SCHEMBL29601112

SCHEMBL29601112

COc1ccc(C(=O)CBr)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.56
DRD3 P35462 1/20 0.46
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
P4HTM Q9NXG6 2/20 0.41
GRIN2B Q13224 2/20 0.41
GRIN1 Q05586 1/20 0.41
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484711 1.00 GSK3B (0.56) GSK3BDRD3HDAC3HDAC4HDAC1
Bromide SCHEMBL27039939 0.98 GSK3B (0.54) GSK3BDRD3HDAC3HDAC4HDAC1
SCHEMBL22065262 0.84 DRD3 (0.47) GSK3BDRD3HDAC3HDAC4HDAC1
Bromide SCHEMBL30518647 0.83 P4HTM (0.44) GSK3BP4HTMALDH1A1CYP1A2POLB
SCHEMBL27039929 0.83 DRD3 (0.46) GSK3BDRD3HDAC3HDAC4HDAC1
SCHEMBL27039826 0.82 ACACB (0.43) GSK3BP4HTMALDH1A1POLBGLA
SCHEMBL31312950 0.81 DRD3 (0.45) DRD3HDAC3HDAC4HDAC1HDAC7
SCHEMBL29023495 0.80 P4HTM (0.39) GSK3BDRD3P4HTMGRIN2BGRIN1
SCHEMBL287134 0.78 P4HTM (0.60) DRD3P4HTMALDH1A1HPGDCYP1A2
SCHEMBL2187078 0.78 DRD3 (0.47) DRD3P4HTMALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232449-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-08-30 EP disclosed
CN-116547282-A Heterocyclic compounds and their use for the treatment of helminth infections and diseases 新基公司 2023-08-04 CN disclosed
WO-2022087326-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-04-28 WO disclosed